🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06949059
Recruiting Phase 1/2

Intravenous Hydromorphone for the Treatment of Acute Pain

NCT06949059 · tracked via the Priya Life Science China tracker
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Phase 1/2
Started
2025-01-01
Last updated
2025-11-17

Condition(s) studied

Acute Chest Pain

Investigational drug(s) / intervention(s)

Hydromorphone

Hydromorphone: Hydromorphone 1mg was given intravenously and conventional treatment was performed at the same time.

Study summary

To observe the efficacy and safety of hydromorphone in the treatment of acute chest pain, and to explore the potential advantages of hydromorphone for analgesia in patients with acute chest pain, so as to provide more theoretical basis for individualized analgesia and rapid recovery in patients with acute chest pain.

Eligibility

Sex
ALL
Min age
18 Years
Max age
64 Years
Healthy volunteers
No
Inclusion criteria: 1. Age 18-64 years old; 2. Gender is not limited; 3. Patients with acute chest pain, with the time from pain onset to visit the doctor ≤ 24 days; 4. Severe pain that requires the use of opioids to control as determined by emergency physicians; 5. Obtain informed consent from the patient or family members. Exclusion criteria: 1. Known allergy to hydromorphone or morphine; 2. Systolic blood pressure \<100 mmHg, oxygen saturation \<95%, pulse less than 60 beats/min; 3. Use of acetaminophen or nonsteroidal anti-inflammatory drugs in the past 8 hours; 4. Chronic pain, defined as pain lasting for more than 12 weeks; 5. Delirium, alcohol withdrawal symptoms or other drug intoxication; 6. Pregnant or lactating women; 7. Patients with mental or neurological diseases, cognitive and consciousness disorders and inability to express correctly; 8. Participating in any other research at the same time; 9. Factors that increase the risk of participating in the study (life-threatening chest pain patients who require rapid diagnosis or treatment intervention, such as resuscitation status, excluding chest pain caused by myocardial infarction), who are judged by the researchers to be unsuitable for inclusion in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nanjing Drum Tower Hospital Nanjing Jiangsu Recruiting

More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06949059 on ClinicalTrials.gov ↗ ← All trials in China